ortd-1
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 29, 2020 (NCT04286789)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
NFKB1 inhibitor
- ADAM17MODULATOR
ADAM17 modulator
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04708236 | Phase 1/Phase 2 (Phase 2) | Apr 30, 2021 | Oryn Therapeutics, LLC, University of California, Irvine |
| NCT04286789 | Phase 1 | Feb 29, 2020 | Oryn Therapeutics, LLC, University of Southern California |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Oryn Therapeutics, LLC | For profit | 2 | 2 | 2 | 2020 |
| University of California, Irvine | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of Southern California | Academic/Hospital | 1 | 0 | 1 | 2020 |
3 organizations
Page 1 / 1